COMPANY PROFILE

BioSyngen

Explore full profile

Clinical-stage CAR-T, TCR-T and TIL cell therapies for solid tumors

Guangzhou, ChinaFounded 2016Biotech & Life Sciences

Valuation $250–500M Last recorded · 2021

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About BioSyngen

BioSyngen is a clinical-stage cell-therapy company developing next-generation CAR-T, TCR-T and TIL immunotherapies for solid tumors (nasopharyngeal, lung, liver and gastrointestinal cancers). Core R&D and GMP manufacturing sit in Guangzhou (Sino-Singapore Guangzhou Knowledge City, Huangpu), with exclusive clinical collaboration at Sun Yat-sen University Cancer Center and trials across multiple China sites; a Singapore corporate office supports dual-site strategy. Proprietary platforms include M-CEL (automated ~10-day cell manufacturing), SUPER-T (tumor-microenvironment-gated safety), MSE-T (functional enhancement) and IDENTIFIER (antigen/antibody/TCR discovery). Pipeline highlights include BRG01 CAR-T (Phase II China/US) and BST02 TIL therapy (IND China/US). Not a Singapore-only startup — China operations are the primary clinical and manufacturing base.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Guangzhou, China
Employees: 17
Open positions: None listed
Dealroom signal: 30.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Oct 2021	$69M	$275M	Science City Group · Skyline Galaxy Capital	—
EARLY VCOther financing	Nov 2019	$0	—	Undisclosed	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

BioSyngen website traffic

Latest recorded traffic for BioSyngen is 60 monthly website visits, down 14.3% over the last three months. BioSyngen's team declined 19% over the past year.

Latest monthly visits60 3-month web change-14.3% 1-year team growth-19%

Monthly website visitsDec 2022–Mar 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HTHarness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs	Babraham, United Kingdom	Operational	5	$35M	$90M
KIKimialysDeveloper of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors	Paris, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
BPBrenus PharmaProducing the widest panel of tumor associated antigens and resistance markers with a chemical labeling enable to induce cell death by patients' immune system	Clermont-Ferrand, France	Operational
EBExeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics	Dijon, France	Operational
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
HPHcs PharmaA company specializing in cell imaging	Loos, France	Operational